New hope for advanced tumors? first human trial of LM-350 begins

NCT ID NCT07112222

Recruiting now Disease control Sponsor: LaNova Medicines Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing an experimental drug called LM-350 in about 80 people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, to find a safe dose and check for side effects; second, to see if the drug can shrink tumors. Participants receive LM-350 by IV every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LM-350 (an experimental drug given by IV every 3 weeks)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early first-in-human trial with only 80 participants, so the drug may not prove safe or effective. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT TUMORS

Contacts and locations

Locations

Beijing Cancer Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, China
Cancer Care Wollongong Pty Limited
RECRUITING

Wollongong, New South Wales, Australia
Cancer Research SA
RECRUITING

Adelaide, South Australia, Australia
Peninsula and South Eastern Haematology and Oncology Group
RECRUITING

Frankston, Victoria, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.